Evropska unija - slovenščina - EMA (European Medicines Agency)

clinuvel europe limited - afamelanotid - protoporfrija, eritropoetik - sproščevalce in zaščitne predmete - preprečevanje fototoksičnosti pri odraslih bolnikih z eritropoetično protoporfirijo (epp).

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

clinuvel (uk) limited - afamelanotid - implantat - afamelanotid 16 mg / 1 implantat - afamelanotid

Evropska unija - slovenščina - EMA (European Medicines Agency)

indivior europe limited - buprenorfin, naloksona - opioidne motnje - druga zdravila na živčnem sistemu - nadomestno zdravljenje odvisnosti od opioidnih drog v okviru zdravstvenega, socialnega in psihološkega zdravljenja. namen komponente naloksona je preprečiti intravensko zlorabo. zdravljenje je namenjeno uporabi pri odraslih in mladostnikih, starejših od 15 let, ki so se strinjali, da se zdravijo zaradi zasvojenosti.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

clinres farmacija d.o.o. - ekstrakt plodu palmeta - kapsula, mehka - ekstrakt plodu palmeta 320 mg / 1 kapsula - plod palmeta

Evropska unija - slovenščina - EMA (European Medicines Agency)

clinigen healthcare b.v. - deksrazoksan hidroklorid - ekstravazacija diagnostičnih in terapevtskih materialov - vsi drugi terapevtski izdelki - zdravilo savene je indicirano za zdravljenje ekstravazacije antraciklina.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

norbrook laboratories (ireland) limited rossmore industrial estate monaghan irska proizvajalec odgovoren za sproščanje serij: norbrook manufacturing ltd -

Evropska unija - slovenščina - EMA (European Medicines Agency)

viatris healthcare limited - imikvimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotiki in kemoterapevtiki za dermatološko uporabo - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Evropska unija - slovenščina - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurija, paroksizmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - kapecitabin - stomach neoplasms; breast neoplasms; colonic neoplasms; colorectal neoplasms - kapecitabin - kapecitabin je indiciran za adjuvantno zdravljenje bolnikov po operaciji stopnje iii (dukes 'stadij c) raka debelega črevesa. capecitabine je primerna za zdravljenje metastatskega raka debelega črevesa in danke. capecitabine je določen za prvo linijo zdravljenja naprednih raka želodca v kombinaciji z platinum, ki temelji režim. capecitabine v kombinaciji z docetaxel je indiciran za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke po okvari citotoksična kemoterapija. predhodno zdravljenje bi moralo vključiti antraciklin. capecitabine je prikazano tudi kot monotherapy za zdravljenje bolnikov z lokalno napredno ali metastatskega raka dojke po okvari taxanes in anthracycline-ki vsebujejo kemoterapijo režim ali za koga še anthracycline zdravljenje ni navedeno.

Evropska unija - slovenščina - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - imunosupresivi - glejte poglavje 4. 1 povzetka glavnih značilnosti zdravila v dokumentu z informacijami o izdelku.